Real-time enrollment status for this metastatic castration resistant prostate cancer clinical trial
Current Status
Recruiting
Checked: September 2, 2026 at 11:24 PM UTC
| NCT Number | NCT07723248 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Castration Resistant Prostate Cancer |
| Phase | PHASE3 |
| Target Enrollment | 600 participants |
| Active Locations | 2 sites in the US |
| Sponsor | ORIC Pharmaceuticals |
| Last Updated on CT.gov | July 23, 2026 (Jul 23, 2026) |
As of September 2, 2026: Clinical trial NCT07723248 is currently recruiting participants. This phase3 study for metastatic castration resistant prostate cancer is actively seeking new participants at 2 locations across the United States. The study is sponsored by ORIC Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07723248 is actively recruiting participants as of September 2, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 2 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07723248 was last updated Jul 23, 2026 (July 23, 2026). HelloStudys verifies this status automatically.